#1 Clinical Trials Search in Europe

Asciminib Hydrochloride

This article explores the use of Asciminib Hydrochloride, a novel drug being studied in clinical trials for the treatment of chronic myeloid leukemia (CML). Asciminib is being investigated as a potential therapy for patients with CML in various phases of the disease, including those who have developed resistance to other treatments. The trials aim to assess the safety, efficacy, and optimal dosing of Asciminib in different patient populations.

Table of Contents

Introduction

Asciminib hydrochloride, also known by its brand name Scemblix, is an innovative medication developed for the treatment of chronic myeloid leukemia (CML). This article will provide a comprehensive overview of asciminib, its uses, effectiveness, and ongoing research to help patients better understand this promising new treatment option.[1]

What is Asciminib?

Asciminib is a novel type of medication known as an allosteric inhibitor. It belongs to a class of drugs called tyrosine kinase inhibitors (TKIs), which are used to treat various types of cancer, including CML. What sets asciminib apart from other TKIs is its unique mechanism of action, which allows it to be effective even in cases where other TKIs have failed.[2]

How Asciminib Works

Asciminib works by targeting a specific protein called BCR-ABL1, which is responsible for the uncontrolled growth of leukemia cells in CML. Unlike other TKIs that bind to the ATP site of the BCR-ABL1 protein, asciminib binds to a different site called the myristoyl pocket. This unique binding mechanism allows asciminib to be effective even in patients who have developed resistance to other TKIs.[3]

Conditions Treated

Asciminib is primarily used to treat chronic myeloid leukemia in chronic phase (CML-CP). It is particularly beneficial for patients who have:

  • Failed treatment with two or more previous TKIs
  • Developed resistance to other TKIs
  • Experienced intolerable side effects from other TKIs
  • A specific mutation called T315I, which makes the leukemia resistant to many other treatments
In some cases, asciminib may also be used to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).[4]

Efficacy

Clinical trials have shown promising results for asciminib in treating CML-CP. In patients who had failed treatment with two or more TKIs, asciminib demonstrated the following:

  • A significant proportion of patients achieved a Major Molecular Response (MMR) within 24 weeks of treatment
  • Many patients maintained their response for extended periods
  • Asciminib was effective in patients with the T315I mutation, who have limited treatment options
These results suggest that asciminib can provide hope for patients who have exhausted other treatment options.[5]

Dosage and Administration

Asciminib is taken orally in the form of tablets. The typical dosage ranges from 20 mg to 200 mg per day, depending on the patient’s specific condition and response to treatment. It’s important to note that:

  • The medication should be taken exactly as prescribed by your doctor
  • Tablets should be swallowed whole and not crushed or chewed
  • Asciminib can be taken with or without food
  • If a dose is missed, it should be taken as soon as remembered, unless it’s close to the next scheduled dose
Your healthcare provider will determine the best dosage for your individual needs.[6]

Side Effects and Safety

Like all medications, asciminib can cause side effects. Common side effects may include:

  • Fatigue
  • Nausea
  • Muscle pain
  • Headache
  • Diarrhea or constipation
  • Rash
More serious side effects, though less common, can include:
  • Pancreatic inflammation
  • Heart rhythm changes
  • Liver problems
It’s crucial to report any side effects to your healthcare provider. They can help manage these effects and adjust your treatment if necessary.[7]

Ongoing Research

Several clinical trials are currently underway to further investigate the potential of asciminib. These studies aim to:

  • Evaluate asciminib as a first-line treatment for newly diagnosed CML patients
  • Assess its effectiveness in combination with other TKIs
  • Investigate its use in pediatric CML patients
  • Explore its potential in treating other types of leukemia
These ongoing studies will provide more information about the long-term efficacy and safety of asciminib, potentially expanding its use to benefit more patients.[7]

Conclusion

Asciminib hydrochloride represents a significant advancement in the treatment of chronic myeloid leukemia, especially for patients who have not responded well to other therapies. Its unique mechanism of action offers hope to those with limited treatment options. As research continues, we may see even more applications for this promising medication in the future. If you have CML and are considering asciminib as a treatment option, discuss it with your healthcare provider to determine if it’s right for you.

Aspect Details
Drug Name Asciminib Hydrochloride (also known as ABL001 or Scemblix)
Type of Drug Tyrosine Kinase Inhibitor (TKI), specifically a STAMP inhibitor
Main Indication Chronic Myeloid Leukemia (CML) in various phases
Key Patient Groups Newly diagnosed CML patients, those resistant/intolerant to other TKIs, patients with T315I mutation
Administration Oral tablets, typically taken once or twice daily
Dosage Range 20-200 mg per dose, depending on the specific trial and patient group
Primary Endpoints Major Molecular Response (MMR), MR4.5, safety and tolerability
Secondary Endpoints Time to response, duration of response, overall survival, progression-free survival
Safety Monitoring Cardiac effects, liver function, pancreatic enzymes, other adverse events
Unique Features Potential efficacy against T315I mutation, novel mechanism of action

FAQ

  • What is Asciminib Hydrochloride? Asciminib Hydrochloride is a new type of drug being studied for the treatment of chronic myeloid leukemia (CML). It works differently from other CML treatments by targeting a specific part of the cancer-causing protein in a new way.
  • Who might benefit from Asciminib treatment? Asciminib is being studied in patients with CML who have not responded well to other treatments, those with a specific genetic mutation called T315I, and even in newly diagnosed patients. It may offer hope for people who have limited treatment options.
  • How is Asciminib given to patients? Asciminib is taken orally as a film-coated tablet. The dosage can vary depending on the specific trial and patient needs, but it is typically taken once or twice daily.
  • What are the main goals of the Asciminib clinical trials? The main goals of these trials are to determine how well Asciminib works in treating CML, how safe it is for patients, what the best dose might be, and how it compares to other existing treatments for CML.
  • Are there any specific side effects associated with Asciminib? While specific side effects can vary, the trials are closely monitoring for any adverse events. Common areas of concern include effects on the heart, liver, and pancreas, as well as general side effects like nausea or fatigue. The full safety profile is still being established through these studies.

Ongoing Clinical Trials on Asciminib Hydrochloride

  • Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Bulgaria Czechia Denmark France Germany +8

  • Study for Adults with Chronic Myeloid Leukemia Using Asciminib Alone or with Nilotinib

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Spain

  • Study of Asciminib treatment for patients with Chronic Myeloid Leukemia who have T315I mutation and cannot take or tolerate ponatinib

    Recruiting

    2 1 1 1
    Investigated drugs:
    France

  • Study of Drug Combination for Advanced Cancer Patients with Known Molecular Profile – FINPROVE Study

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland

  • Study on the Dose and Safety of Asciminib in Children with Chronic Myeloid Leukemia

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Germany Greece Hungary Italy The Netherlands +1

  • Safety and effectiveness of ponatinib and asciminib in chronic myeloid leukemia patients resistant to these drugs

    Not yet recruiting

    2 1 1 1
    Investigated drugs:
    Spain

  • Asciminib in Pediatric Patients With Philadelphia Positive Chronic Myeloid Leukemia in Chronic Phase

    Not yet recruiting

    2 1 1 1
    Investigated drugs:
    France Germany Italy The Netherlands Poland Spain

  • Study of asciminib, dexamethasone, blinatumomab, and vincristine sulfate in children and young adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany Italy The Netherlands +1

  • Study of treatment discontinuation with nilotinib and asciminib in adults with chronic myeloid leukemia to achieve treatment-free remission

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Italy

  • Study on the Effectiveness of Asciminib and Imatinib for Patients with Chronic Myelogenous Leukemia Not Responding to Imatinib

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Austria Czechia France Italy Spain

Glossary

  • Chronic Myeloid Leukemia (CML): A type of blood cancer that begins in the bone marrow and affects the production of white blood cells. It typically progresses slowly and is characterized by the presence of an abnormal chromosome called the Philadelphia chromosome.
  • Philadelphia Chromosome: An abnormal chromosome found in CML cells. It's formed when parts of chromosomes 9 and 22 switch places, creating a fusion gene called BCR-ABL that leads to uncontrolled cell growth.
  • Tyrosine Kinase Inhibitor (TKI): A class of drugs used to treat CML that work by blocking the action of tyrosine kinases, enzymes that are overactive in CML cells. Asciminib is a new type of TKI that works differently from earlier generations.
  • T315I Mutation: A specific genetic change in the BCR-ABL gene that makes CML resistant to many standard TKI treatments. Asciminib is being studied as a potential treatment for patients with this mutation.
  • Major Molecular Response (MMR): A measure of treatment success in CML, defined as a very low level of BCR-ABL gene in the blood (0.1% or less on a standardized scale).
  • BCR-ABL: The abnormal gene created by the Philadelphia chromosome. It produces a protein that causes the uncontrolled growth of leukemia cells in CML.
  • Chronic Phase CML: The earliest phase of CML, where less than 10% of cells in the blood and bone marrow are immature leukemia cells (blasts). Most patients are diagnosed in this phase.
  • Accelerated Phase CML: A more advanced phase of CML where 10-19% of cells in the blood or bone marrow are blasts. The disease progresses faster in this phase.
  • Blast Phase CML: The most advanced phase of CML, also called blast crisis, where 20% or more of the cells in the blood or bone marrow are blasts. It behaves like an acute leukemia.
  • Molecular Response: A measure of how well CML treatment is working, based on the amount of BCR-ABL gene detected in the blood. Deeper responses (like MR4.0 or MR4.5) indicate better disease control.

References

  1. http://clinicaltrials.eu/trial/2023-507557-16-00
  2. http://clinicaltrials.eu/trial/2023-508129-28-00
  3. http://clinicaltrials.eu/trial/2023-508838-33-00
  4. http://clinicaltrials.eu/trial/2024-510947-71-00
  5. http://clinicaltrials.eu/trial/2024-511381-36-00
  6. http://clinicaltrials.eu/trial/2024-515040-23-00
  7. http://clinicaltrials.eu/trial/2024-516049-38-00